- Policy
- The administration monitoring cycle of Samsca is changed
- by Kim, Jung-Ju Jul 22, 2021 05:53am
- The administration monitoring cycle of Samsca (Tolvaptan) is changed in more detail. Psoriasis arthritis treatment Ixekizumab, which have been used as secondary drugs, and Secukinumab such as Cosentyx will be expanded to primary biological treatments. The MOHW announced on the 20th a partial revision of the "Details on the Standards and Meth
- Policy
- GSK & SK Bio also stopped supplying TD vaccines
- by Lee, Tak-Sun Jul 21, 2021 05:51am
- SK Bioscience will also withdraw its products from the TD vaccine market that prevents diphtheria and tetanus in adults. GSK, which had been importing and supplying TD vaccines last year, also stopped supplying them in the Korean market. As a result, GC Pharma, which is manufacturing domestic drugs, is expected to strengthen its position in t
- Policy
- CSO expenditure report Act, effective immediately
- by Lee, Jeong-Hwan Jul 20, 2021 05:47am
- The government promulgated the revised Pharmacist Act today (20th), which includes restrictions on co-living and clinical 1+3 of generic and new drugs and mandatory preparation of CSO expenditure reports. In accordance with the revised Pharmaceutical Law, restrictions on 1+3 generic and improvement new drugs and regulations requiring CSOs
- Policy
- Kymriah reimbursement was not discussed at CDRC meeting
- by Lee, Jeong-Hwan Jul 20, 2021 05:47am
- The Korea Leukemia Patients Organization (KLPO) expressed its regrets to the government and Novartis Korea for excluding the first CAR-T treatment Kymriah from the agenda for deliberation at the Review Committee for Cancer Diseases meeting that was held on the 14th. On the 19th, KLPO said, “A disconcerting situation occurred. Kymriah wa
- Policy
- Pfizer vaccine available in Korea for ages 12 or older
- by Lee, Tak-Sun Jul 20, 2021 05:46am
- Pfizer's COVID-19 vaccine has become available in Korea for people over 12 years of age. The MFDS announced on the 16th that it has approved the change of Comirnaty, which can be used to prevent COVID-19 among people aged 12 and older. The dosage and indications of the vaccine can be diluted once with 0.3ml and inoculated additionally a
- Policy
- Aduhel has been applied for permission in Korea
- by Lee, Tak-Sun Jul 19, 2021 05:56am
- Recently, Aduhel (Aducanumab), a new drug for Alzheimer's disease approved by the U.S. Food and Drug Administration (FDA), has applied for permission in Korea. Aduhel is a new drug for Alzheimer's disease approved by the U.S. FDA in 18 years, the first drug to target the amino acid peptide β-amyloid known to be involved in the disease.
- Policy
- Once 'out of stock' Bayer Aspirin 100mg to be discontinued
- by Lee, Tak-Sun Jul 16, 2021 05:54am
- Bayer decided to discontinue domestic supply of its antipyretic analgesic, ‘Bayer Aspirin 100mg.’ Despite the company’s explanation that the decision was made due to poor sales, the pharmacys’ eyes are not so kind on the company's decision as they have suffered shortages of stock issues regarding the product. According to the Ministry
- Policy
- 2nd AZ·Pfizer·Moderna shot prevents variants by 80%
- by Lee, Hye-Kyung Jul 16, 2021 05:54am
- Study results on the preventive effect of the AstraZeneca, Pfizer, and Moderna vaccine against variants showed that the vaccines had a preventive effect of over 80% after completing the two-dose regimen. The prevention effect was greater against the Alpha variant than the Delta. In preventing symptomatic infections, the vaccines had a sim
- Policy
- Patients with SCLS shouldn't get Janssen vaccine
- by Lee, Tak-Sun Jul 16, 2021 05:54am
- The MFDS said Janssen COVID-19 vaccine should not be vaccinated for people with a history of Systemic Capillary Leak Syndrome (SCLS). This is in accordance with the European EMA recommendation and is similar to the action that was taken on the AstraZeneca vaccine on the 14th of last month. The MFDS released the Dear Healthcare Professi
- Policy
- Generic for Galvusmet was first approved
- by Lee, Tak-Sun Jul 16, 2021 05:54am
- The timing of the sale varies depending on the results of the Supreme Court's lawsuit against the validity of the patent. Hanmi has been approved for the first time in Korea as a generic for Galvusmet, a diabetes complex affiliated with Novartis' DPP-4 inhibitor. Hanmi developed Vildagliptin HCl and licensed both single and multi-drugs in
